{"id":20463,"date":"2022-01-18T13:48:36","date_gmt":"2022-01-18T19:48:36","guid":{"rendered":"https:\/\/cancer.wisc.edu\/research\/?p=20463"},"modified":"2022-01-18T13:48:36","modified_gmt":"2022-01-18T19:48:36","slug":"circulating-biomarker-core-highlight-2","status":"publish","type":"post","link":"https:\/\/cancer.wisc.edu\/research\/circulating-biomarker-core-highlight-2\/","title":{"rendered":"Circulating Biomarker Core Highlight"},"content":{"rendered":"<p>Since its inception, the CBC has supported 43 different projects, including 14 clinical trials (90% investigator-initiated), with 23 different NCI-designated cancer centers, 35 unique investigators (66% UWCCC members) from multiple Universities (UWCCC, Dana Farber Cancer Institute, etc.), looking at 9 different types of cancer, involving NCI cooperative groups (Alliance and NRG), the BigTen clinical trials network, the Prostate Cancer Clinical Trials Consortium (PCCTC) and pharmaceutical companies (AstraZeneca, Bristol-Myers Squibb, etc.). These liquid biopsy clinical trials have spanned multiple solid tumor diseases: Prostate: Kyriakopoulos NCT03358563, Wei NCT04126070, Lang NCT03725761, Renal: Kyriakopoulos NCT03203473, McKay NCT04071223*, McKay SAMURAI*, Breast: O&#8217;Regan NCT03090165, Parkes NCT04762979, Fowler NCT04174352, Wisinski NCT04174352, Wisinski NCT03186937, Lung: Bassetti NCT03275597, Leal NCT03965689*, Morris NCT04936841 (*denotes NCI funded).<\/p>\n<p>Our faculty director Josh Lang, MD, MS leads the core with the help of Co-Director and CLIA Consultant, Kaitlin Sundling, MD, PhD, and Co-Director and Lead Bioinformatician, George Zhao, MD, MSE. Visit our website for more details: <a href=\"https:\/\/cancer.wisc.edu\/research\/resources\/cbc\/\">https:\/\/cancer.wisc.edu\/research\/resources\/cbc\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Since its inception, the CBC has supported 43 different projects, including 14 clinical trials (90% investigator-initiated), with 23 different NCI-designated cancer centers, 35 unique investigators (66% UWCCC members) from multiple Universities (UWCCC, Dana Farber Cancer &hellip;<\/p>\n","protected":false},"author":61,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[166],"tags":[],"class_list":["post-20463","post","type-post","status-publish","format-standard","hentry","category-cbc"],"acf":[],"_links":{"self":[{"href":"https:\/\/cancer.wisc.edu\/research\/wp-json\/wp\/v2\/posts\/20463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cancer.wisc.edu\/research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cancer.wisc.edu\/research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cancer.wisc.edu\/research\/wp-json\/wp\/v2\/users\/61"}],"replies":[{"embeddable":true,"href":"https:\/\/cancer.wisc.edu\/research\/wp-json\/wp\/v2\/comments?post=20463"}],"version-history":[{"count":1,"href":"https:\/\/cancer.wisc.edu\/research\/wp-json\/wp\/v2\/posts\/20463\/revisions"}],"predecessor-version":[{"id":20464,"href":"https:\/\/cancer.wisc.edu\/research\/wp-json\/wp\/v2\/posts\/20463\/revisions\/20464"}],"wp:attachment":[{"href":"https:\/\/cancer.wisc.edu\/research\/wp-json\/wp\/v2\/media?parent=20463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cancer.wisc.edu\/research\/wp-json\/wp\/v2\/categories?post=20463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cancer.wisc.edu\/research\/wp-json\/wp\/v2\/tags?post=20463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}